The human gut is home to trillions of beneficial bacteria and other microorganisms that can have a positive impact on a range of chronic human ailments. Research suggests that these microorganisms can reduce the risk of obesity, type 2 diabetes, atherosclerosis, cancer, non-alcoholic fatty liver disease, and inflammatory bowel disease.
This remarkable discovery highlights the importance of maintaining a healthy gut in order to achieve optimal health.
By engineering native bacteria to express transgenes capable of inducing persistent and potentially curative therapeutic changes in the gut, researchers have demonstrated the potential of live bacterial therapeutics for treating a variety of chronic human ailments.
This method has shown to be successful in providing long-term therapy in a mouse model of type 2 diabetes, and the same approach may be used to engineer human native bacteria for therapeutic delivery.
Live bacterial therapeutics may offer a promising, non-invasive, low risk and cost-effective option for treating many diseases.
Live Bacterial Therapeutics (LBTs) is a revolutionary approach to improving the health of microbial communities by engineering bacterial hosts to produce therapeutics that can help to restore or repair healthy microbial function and diversity.
With this approach, scientists are able to develop customized treatments that target specific microbial communities and work to improve their overall health. This technology has the potential to revolutionize the way we think about treating microbial diseases and could lead to better outcomes for patients suffering from a variety of conditions.
The study showed promise in a mouse model that this type of therapy can be effective at treating Type 2 diabetes and possibly other diseases like cancer.
Read More – UC San Diego
